VWF and platelet-type von Willebrand disease: In a non-cancer setting, dDAVP is the treatment of choice in patients with von Willebrand disease (VWD; a genetic disorder caused by reduced or dysfunctional VWF) to stimulate the release of endogenous VWF into the plasma [97].